Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Warren Capell

Concepts (175)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Rivaroxaban
16
2026
270
2.470
Why?
Peripheral Arterial Disease
17
2026
507
2.020
Why?
Aspirin
14
2026
405
1.680
Why?
Factor Xa Inhibitors
9
2026
195
1.600
Why?
Lower Extremity
13
2026
453
1.390
Why?
Endovascular Procedures
6
2026
390
0.930
Why?
Platelet Aggregation Inhibitors
12
2026
499
0.900
Why?
Beneficence
1
2021
20
0.650
Why?
Research Subjects
1
2021
42
0.640
Why?
Hypertriglyceridemia
3
2006
45
0.640
Why?
Personal Autonomy
1
2021
61
0.630
Why?
Thrombosis
2
2022
398
0.620
Why?
Informed Consent
2
2021
195
0.610
Why?
Ischemia
6
2024
421
0.590
Why?
Patient Selection
2
2021
728
0.570
Why?
Outpatients
1
2021
440
0.500
Why?
Double-Blind Method
9
2026
2070
0.420
Why?
Drug Therapy, Combination
9
2026
1036
0.410
Why?
Vascular Surgical Procedures
4
2026
352
0.390
Why?
Venous Thromboembolism
3
2023
332
0.390
Why?
Lipoprotein Lipase
2
2010
55
0.360
Why?
Lipoproteins
4
2010
165
0.350
Why?
Risk Assessment
1
2021
3712
0.330
Why?
Hospitalization
2
2021
2475
0.330
Why?
Hypolipidemic Agents
3
2006
89
0.330
Why?
Fat Emulsions, Intravenous
1
2010
29
0.310
Why?
Clinical Trials, Phase III as Topic
2
2021
116
0.290
Why?
Multicenter Studies as Topic
3
2021
417
0.280
Why?
Hemorrhage
6
2026
825
0.270
Why?
Coronary Artery Disease
2
2024
751
0.260
Why?
Randomized Controlled Trials as Topic
4
2024
1763
0.240
Why?
Triglycerides
3
2010
527
0.240
Why?
Euthyroid Sick Syndromes
1
2026
6
0.240
Why?
Thyrotropin
1
2026
120
0.230
Why?
Thyroid Gland
1
2026
93
0.220
Why?
Glucose
1
2010
1053
0.210
Why?
Middle Aged
18
2026
36619
0.210
Why?
Myocardial Infarction
2
2022
1215
0.200
Why?
Male
24
2026
73396
0.200
Why?
Treatment Outcome
10
2026
11821
0.190
Why?
Fatty Acids, Nonesterified
3
2010
154
0.190
Why?
Fenofibrate
1
2003
28
0.190
Why?
Fibrin Fibrinogen Degradation Products
1
2023
92
0.190
Why?
Antifibrinolytic Agents
1
2023
68
0.180
Why?
Humans
33
2026
146342
0.180
Why?
Female
22
2026
79499
0.180
Why?
Muscle, Skeletal
2
2010
1818
0.170
Why?
Drug-Eluting Stents
1
2021
88
0.170
Why?
Blood Coagulation Disorders
1
2023
190
0.160
Why?
Placebos
1
2021
192
0.160
Why?
Paclitaxel
1
2021
260
0.160
Why?
Pragmatic Clinical Trials as Topic
1
2021
135
0.160
Why?
Postoperative Complications
2
2024
3034
0.150
Why?
Extremities
1
2021
142
0.150
Why?
Clinical Trials as Topic
3
2021
1064
0.150
Why?
Follow-Up Studies
2
2021
5439
0.150
Why?
Vasodilation
1
2003
519
0.150
Why?
Aged
13
2026
26432
0.140
Why?
Cause of Death
1
2021
456
0.140
Why?
Subacute Care
1
2019
85
0.140
Why?
Brain Ischemia
1
2021
362
0.130
Why?
Dose-Response Relationship, Drug
2
2021
2022
0.130
Why?
Purinergic P2Y Receptor Antagonists
1
2018
71
0.130
Why?
Nursing Homes
1
2019
171
0.130
Why?
Health Services Research
1
2019
390
0.120
Why?
Hospital Mortality
1
2021
1051
0.120
Why?
Lipoproteins, LDL
1
1996
119
0.120
Why?
Skilled Nursing Facilities
1
2017
152
0.110
Why?
Insulin Resistance
3
2013
1247
0.100
Why?
Fibrinolytic Agents
1
2017
303
0.100
Why?
Ethics, Research
1
2014
33
0.100
Why?
Diabetes Mellitus, Type 2
2
2024
2623
0.100
Why?
Disease Management
1
2017
651
0.090
Why?
Societies, Medical
1
2017
907
0.090
Why?
Anticoagulants
3
2023
746
0.090
Why?
Caspase 1
1
2013
145
0.090
Why?
Stroke
1
2021
1287
0.090
Why?
Cardiovascular Diseases
2
2021
2219
0.090
Why?
Interleukin-18
1
2013
234
0.090
Why?
Heparin
2
2023
247
0.080
Why?
Interleukin-1beta
1
2013
397
0.080
Why?
Research Design
1
2017
1143
0.080
Why?
Arteries
2
2022
261
0.080
Why?
Biomedical Research
1
2017
729
0.080
Why?
Transfection
2
2010
916
0.080
Why?
Lactones
1
2010
60
0.080
Why?
Dietary Fats
2
2010
307
0.080
Why?
Myoblasts
1
2010
84
0.080
Why?
Diet, Carbohydrate-Restricted
1
2010
36
0.080
Why?
Diet, Fat-Restricted
2
2010
79
0.070
Why?
Hypercholesterolemia
1
2010
95
0.070
Why?
Kaplan-Meier Estimate
2
2021
970
0.070
Why?
Obesity
2
2013
3131
0.070
Why?
Blotting, Western
1
2010
1177
0.070
Why?
Inflammation
2
2023
2919
0.060
Why?
Simvastatin
1
2006
58
0.060
Why?
Thyroid Function Tests
1
2026
19
0.060
Why?
Triiodothyronine
1
2026
55
0.060
Why?
Thyroxine
1
2026
67
0.060
Why?
Temperance
1
2005
20
0.060
Why?
Limb Salvage
1
2026
74
0.060
Why?
Palliative Care
1
2014
1032
0.060
Why?
Anticholesteremic Agents
1
2006
156
0.050
Why?
Adult
5
2021
41087
0.050
Why?
Cell Line
1
2010
2814
0.050
Why?
Treatment Failure
1
2005
361
0.050
Why?
Cross-Over Studies
2
2006
615
0.050
Why?
Practice Guidelines as Topic
2
2017
1591
0.050
Why?
C-Reactive Protein
1
2006
429
0.050
Why?
Weight Loss
1
2010
858
0.050
Why?
Incidence
2
2021
2936
0.050
Why?
Risk Factors
3
2026
10921
0.050
Why?
Thromboplastin
1
2023
67
0.050
Why?
Angiography
1
2024
206
0.050
Why?
Heart Failure
1
2017
2329
0.050
Why?
Aged, 80 and over
2
2026
8391
0.050
Why?
Hydroxymethylglutaryl-CoA Reductase Inhibitors
1
2006
449
0.050
Why?
Vesicular Transport Proteins
1
2003
85
0.050
Why?
Forearm
1
2003
141
0.050
Why?
Numbers Needed To Treat
1
2021
7
0.040
Why?
Metabolic Syndrome
1
2005
364
0.040
Why?
Prospective Studies
2
2026
8123
0.040
Why?
Fasting
1
2003
280
0.040
Why?
Frailty
1
2024
208
0.040
Why?
Regional Blood Flow
1
2003
507
0.040
Why?
Postmenopause
1
2003
394
0.040
Why?
Antineoplastic Agents, Phytogenic
1
2021
178
0.040
Why?
Atherosclerosis
1
2024
410
0.040
Why?
Muscle, Smooth, Vascular
1
2003
449
0.040
Why?
Internationality
1
2020
156
0.040
Why?
Time Factors
2
2026
7109
0.040
Why?
Lipid Metabolism
1
2003
533
0.040
Why?
Nerve Tissue Proteins
1
2003
597
0.040
Why?
Confidentiality
1
2019
82
0.030
Why?
Acute Disease
1
2021
1038
0.030
Why?
Alcohol Drinking
1
2005
850
0.030
Why?
Algorithms
1
2006
1849
0.030
Why?
Mice
3
2013
18297
0.030
Why?
Proportional Hazards Models
1
2021
1331
0.030
Why?
Global Health
1
2021
403
0.030
Why?
Proteins
1
2003
1022
0.030
Why?
Combined Modality Therapy
1
2020
1271
0.030
Why?
Membrane Proteins
1
2003
1130
0.030
Why?
Arteriosclerosis
1
1996
82
0.030
Why?
Cholesterol, LDL
2
2010
363
0.030
Why?
Patient Safety
1
2019
352
0.030
Why?
Particle Size
1
1996
386
0.030
Why?
Reference Values
1
1996
796
0.030
Why?
Disease Susceptibility
1
1996
339
0.030
Why?
Ethics Committees, Research
1
2014
41
0.030
Why?
Patient Transfer
1
2017
224
0.020
Why?
Animals
3
2013
38107
0.020
Why?
Research Personnel
1
2014
190
0.020
Why?
Diet, High-Fat
1
2013
267
0.020
Why?
Cohort Studies
1
2022
6077
0.020
Why?
Diet, Reducing
1
2010
90
0.020
Why?
Dietary Carbohydrates
1
2010
146
0.020
Why?
Body Weight
1
2013
968
0.020
Why?
Phenotype
1
1996
3206
0.020
Why?
Quality Improvement
1
2017
1354
0.020
Why?
Communication
1
2014
980
0.020
Why?
Sex Factors
1
2013
2107
0.020
Why?
Energy Intake
1
2010
507
0.020
Why?
Mice, Knockout
1
2013
3125
0.010
Why?
Dyslipidemias
1
2006
184
0.010
Why?
Retrospective Studies
1
2003
17438
0.010
Why?
Munc18 Proteins
1
2003
26
0.010
Why?
SNARE Proteins
1
2003
42
0.010
Why?
Muscle Fibers, Skeletal
1
2003
216
0.010
Why?
Oligonucleotide Array Sequence Analysis
1
2003
752
0.010
Why?
Reverse Transcriptase Polymerase Chain Reaction
1
2003
974
0.010
Why?
Insulin
1
2010
2525
0.010
Why?
Mice, Transgenic
1
2003
2134
0.010
Why?
Cells, Cultured
1
2003
4118
0.010
Why?
Blood Glucose
1
2003
2360
0.010
Why?
Capell's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)